Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019942080> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2019942080 endingPage "1396" @default.
- W2019942080 startingPage "1390" @default.
- W2019942080 abstract "The optimal dosage and clinical efficacy of vinblastine (VBL) for treatment of mast cell tumors (MCTs) in dogs has not been established.Single-agent VBL has antitumor activity against MCTs in dogs.Fifty-one dogs with nonresectable grade II or III cutaneous MCTs.Prospective, open clinical trial. Dogs were systematically allocated (by hospital record number) to receive IV treatment with VBL at a dosage of 2.0 mg/m2 (weekly for 4 treatments then biweekly for 4 treatments; VBL 2.0) or treatment with VBL at a dosage of 3.5 mg/m2 (biweekly for 5 treatments; VBL 3.5). The primary outcome measure was reduction in tumor size.Twenty-five dogs were allocated to the VBL 2.0 group and 26 were allocated to the VBL 3.5 group. In the VBL 2.0 group, 3 (12%) had a partial response (PR) for a median of 77 days (range, 48-229 days). Overall response rate in the VBL 3.5 group was 27%. One dog (4%) had a complete response for 63 days and 6 dogs (23%) had a PR for a median of 28 days (range, 28-78 days). Toxicoses were uncommon in the VBL 2.0 group. Twelve (46%) dogs in the VBL 3.5 group had < 500 neutrophils/microL 7 days after treatment; 2 dogs with neutropenia developed concurrent fevers.VBL, when used as a single-agent, has activity against MCTs in dogs although the response rate is lower than those reported for VBL-containing combination protocols. Further, findings suggest VBL at a dosage of 3.5 mg/m2 should be considered for use in future phase II/III trials." @default.
- W2019942080 created "2016-06-24" @default.
- W2019942080 creator A5008398870 @default.
- W2019942080 creator A5026352905 @default.
- W2019942080 creator A5040575182 @default.
- W2019942080 creator A5041720417 @default.
- W2019942080 creator A5049261476 @default.
- W2019942080 creator A5068354829 @default.
- W2019942080 creator A5044697737 @default.
- W2019942080 date "2008-10-30" @default.
- W2019942080 modified "2023-10-18" @default.
- W2019942080 title "Efficacy of Vinblastine for Treatment of Canine Mast Cell Tumors" @default.
- W2019942080 cites W1980212444 @default.
- W2019942080 cites W1983783702 @default.
- W2019942080 cites W2011245851 @default.
- W2019942080 cites W2024357525 @default.
- W2019942080 cites W2024451570 @default.
- W2019942080 cites W2029409133 @default.
- W2019942080 cites W2073693702 @default.
- W2019942080 cites W2078200326 @default.
- W2019942080 cites W2092868924 @default.
- W2019942080 cites W2131754078 @default.
- W2019942080 cites W2140011311 @default.
- W2019942080 cites W4206510860 @default.
- W2019942080 cites W4235987765 @default.
- W2019942080 cites W4244211276 @default.
- W2019942080 doi "https://doi.org/10.1111/j.1939-1676.2008.0195.x" @default.
- W2019942080 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19000249" @default.
- W2019942080 hasPublicationYear "2008" @default.
- W2019942080 type Work @default.
- W2019942080 sameAs 2019942080 @default.
- W2019942080 citedByCount "41" @default.
- W2019942080 countsByYear W20199420802012 @default.
- W2019942080 countsByYear W20199420802013 @default.
- W2019942080 countsByYear W20199420802014 @default.
- W2019942080 countsByYear W20199420802016 @default.
- W2019942080 countsByYear W20199420802017 @default.
- W2019942080 countsByYear W20199420802018 @default.
- W2019942080 countsByYear W20199420802019 @default.
- W2019942080 countsByYear W20199420802020 @default.
- W2019942080 countsByYear W20199420802021 @default.
- W2019942080 countsByYear W20199420802022 @default.
- W2019942080 countsByYear W20199420802023 @default.
- W2019942080 crossrefType "journal-article" @default.
- W2019942080 hasAuthorship W2019942080A5008398870 @default.
- W2019942080 hasAuthorship W2019942080A5026352905 @default.
- W2019942080 hasAuthorship W2019942080A5040575182 @default.
- W2019942080 hasAuthorship W2019942080A5041720417 @default.
- W2019942080 hasAuthorship W2019942080A5044697737 @default.
- W2019942080 hasAuthorship W2019942080A5049261476 @default.
- W2019942080 hasAuthorship W2019942080A5068354829 @default.
- W2019942080 hasBestOaLocation W20199420801 @default.
- W2019942080 hasConcept C126322002 @default.
- W2019942080 hasConcept C141071460 @default.
- W2019942080 hasConcept C2776694085 @default.
- W2019942080 hasConcept C2777063308 @default.
- W2019942080 hasConcept C2777132456 @default.
- W2019942080 hasConcept C71924100 @default.
- W2019942080 hasConcept C90924648 @default.
- W2019942080 hasConceptScore W2019942080C126322002 @default.
- W2019942080 hasConceptScore W2019942080C141071460 @default.
- W2019942080 hasConceptScore W2019942080C2776694085 @default.
- W2019942080 hasConceptScore W2019942080C2777063308 @default.
- W2019942080 hasConceptScore W2019942080C2777132456 @default.
- W2019942080 hasConceptScore W2019942080C71924100 @default.
- W2019942080 hasConceptScore W2019942080C90924648 @default.
- W2019942080 hasIssue "6" @default.
- W2019942080 hasLocation W20199420801 @default.
- W2019942080 hasLocation W20199420802 @default.
- W2019942080 hasOpenAccess W2019942080 @default.
- W2019942080 hasPrimaryLocation W20199420801 @default.
- W2019942080 hasRelatedWork W1519773982 @default.
- W2019942080 hasRelatedWork W1965964706 @default.
- W2019942080 hasRelatedWork W2019246554 @default.
- W2019942080 hasRelatedWork W2047367673 @default.
- W2019942080 hasRelatedWork W2098612596 @default.
- W2019942080 hasRelatedWork W2369324096 @default.
- W2019942080 hasRelatedWork W2413365644 @default.
- W2019942080 hasRelatedWork W243427647 @default.
- W2019942080 hasRelatedWork W36464137 @default.
- W2019942080 hasRelatedWork W4238093267 @default.
- W2019942080 hasVolume "22" @default.
- W2019942080 isParatext "false" @default.
- W2019942080 isRetracted "false" @default.
- W2019942080 magId "2019942080" @default.
- W2019942080 workType "article" @default.